Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 16.29M | 17.78M | 12.23M | 5.88M | 2.53M | 2.43M |
Gross Profit | 7.10M | 7.85M | 6.15M | 2.86M | 1.10M | 1.23M |
EBITDA | -5.13M | -4.06M | -4.19M | -5.10M | -6.70M | -7.83M |
Net Income | -3.15M | -2.40M | -3.50M | -4.50M | -7.38M | -10.47M |
Balance Sheet | ||||||
Total Assets | 10.51M | 10.51M | 8.21M | 4.86M | 3.02M | 4.94M |
Cash, Cash Equivalents and Short-Term Investments | 2.56M | 3.55M | 3.54M | 1.85M | 962.00K | 716.00K |
Total Debt | 1.43M | 2.55M | 1.70M | 1.47M | 1.13M | 2.67M |
Total Liabilities | 2.05M | 4.46M | 4.00M | 2.85M | 2.09M | 5.18M |
Stockholders Equity | 7.61M | 8.85M | 6.84M | 4.88M | 4.65M | 3.86M |
Cash Flow | ||||||
Free Cash Flow | -5.89M | -4.44M | -2.84M | -3.03M | -3.97M | -4.18M |
Operating Cash Flow | -5.52M | -3.21M | -2.37M | -2.76M | -3.94M | -4.15M |
Investing Cash Flow | -454.00K | -1.32M | -478.00K | -271.00K | -34.00K | -123.00K |
Financing Cash Flow | 4.22M | 4.44M | 4.66M | 3.96M | 4.23M | 4.34M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
73 Outperform | $516.66M | 4.44 | 11.76% | 1.77% | 7.82% | 19465.71% | |
55 Neutral | $583.65M | ― | -5.28% | ― | -4.23% | -259.01% | |
54 Neutral | $276.45M | ― | -10.12% | ― | 2.20% | 34.71% | |
54 Neutral | $176.97M | 11.43 | -3.29% | 5.75% | -33.92% | -58.53% | |
53 Neutral | $84.36M | ― | -26.63% | ― | -11.91% | -26768.00% | |
49 Neutral | $60.88M | ― | -40.03% | ― | 22.97% | 17.32% | |
43 Neutral | AU$1.41B | -6.02 | -40.74% | 3.99% | -3.45% | -41.76% |
At its 2025 annual stockholder meeting on June 19, 2025, BioLargo, Inc. announced the approval of all proposals, including the election of board members and the authorization for a potential reverse stock split. Although the reverse stock split was approved, the board has no immediate plans to implement it, intending to do so only if necessary for uplisting to a national exchange. CEO Dennis Calvert highlighted the company’s strategic positioning and readiness to expand its market reach and attract institutional investors when conditions are favorable.
BioLargo, Inc. presented a slide presentation at a webcast investor conference on May 15, 2025. The information shared during this event is not considered filed with the SEC and the company does not have an obligation to update it, although it may choose to do so in the future.